Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Rabies virus
Zoetis UK Limited
QI07AA02
Rabies virus
Suspension for injection
POM-V - Prescription Only Medicine – Veterinarian
Cats, Dogs
Inactivated Viral Vaccine
Expired
2000-05-23
Revised: October 2015 Minor amendment to section 6.1 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE IMMUNOLOGICAL VETERINARY PRODUCT Vanguard Rabies 2. QUALITATIVE AND QUANTITATIVE COMPOSITION QUANTITY/DOSE ACTIVE CONSTITUENTS: Rabies Virus (Strain Flury LEP) (Inactivated, concentrated and purified rabies virus antigen * Based on Ph. Eur. serology test) ≥ 3.25 IU/ml of Rabies glycoprotein inducing ≥ 1.4 log10 IU/ml* ADJUVANT: Aluminium Hydroxide 1.7-2.1 mg For full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Vanguard Rabies vaccine is a sterile opaque suspension for subcutaneous injection, with an off-white precipitate which readily resuspends on shaking. 4. CLINICAL PARTICULARS 4.1. TARGET SPECIES Cats, dogs. 4.2. INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the active immunisation of cats and dogs to prevent infection and mortality due to rabies. An antibody response normally develops within 7-14 days after vaccination. Vaccinated animals should not be exposed to the risk of rabies infection for 14 days. The specific immune response confers immunity for up to 3 years. 4.3. CONTRAINDICATIONS Do not use in unhealthy animals. Do not use in pregnant animals. 4.4. SPECIAL WARNINGS FOR EACH TARGET SPECIES None. Revised: October 2015 Minor amendment to section 6.1 Page 2 of 5 4.5. SPECIAL PRECAUTIONS FOR USE i) Special precautions for use in animals Do not vaccinate animals for at least one month following the administration of immuno-suppressive drugs. ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals No special precautions apply. 4.6. ADVERSE REACTIONS As with all vaccines, occasional hypersensitivity may occur. In such cases, appropriate treatment, such as adrenalin, should be administered without delay. In dogs, treatment with the vaccine produces oedematous swelling of up to 3.8 cm maximum diameter (5.4 cm 3 max. volume) at the site of injection. This swelling resolves with time and disappears by 21 days after tr Read the complete document